Innovation in the commercialization of new medicines: the 4 pillars from the Marketing Authorization to Market Access
This is a Workshop in which the speakers are representative of the four pillars: evaluation and authorization of the medicinal product, represented by the Spanish Agency of Medicines (AEMPS) with the Spanish representative from the Committee of Advanced Therapies (CAT), the Hospital Drug Product Access through the Pharmacotherapeutic Guidelines with a representative of the Spanish Society of Hospital Pharmacy (SEFH), the Market Access from the pharmaceutical industry, with a Responsible of a Department of Pharmacoeconomics in BMS and the Regulatory Affairs with a Qualified Person and RA Director from Mundipharma.
The moderator of the table is one of the leaders in the world of Pharma Market Access, Health Economics and Outcomes Reseach/Pricing and Reimbursement, with extended teaching experience:
-Jose Manuel Rodriguez Barrios. Health Economics, Pricing and Market Access Strategy Europe Director, Daiichi Sankyo Europe.
KEYWORDS & TOPICS
Speaker: Sol Ruiz Antúnez
Institution: Head of Sector of Biotechnology and Advanced Therapies at the Spanish Medicines Agency- CAT member and and a co-opted member of the CHMP (Committee for Human Medicinal Products) at European Medicines Agency.
Speaker: Paloma González
Institution: Head Economics and Outcomes Research Department – Bristol-Myers Squibb.
Speaker: José Manuel Rodriguez Barrios
Institution: Economics, Pricing and Market Access Strategy Director Europe, Daiichi Sankyo Europe.
Speaker: Mª Dolores Fraga Fuentes
Institution: Coordinator at GRUPO GENESIS from SEFH).
Speaker: Mª José Sancho González
Institution: QP and Regulatory Affairs Director – Mundipharma.
Names: Raquel Carnero Gómez
Institution: University of Salamanca, Spain.